Cara Therapeutics (CARA)

P/S ratio as of December 2024 (TTM): 2.65

According to Cara Therapeutics 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 32.6. At the end of 2024 the company had a P/S ratio of 1.93.

P/S ratio history for Cara Therapeutics from 2014 to 2024

PS ratio at the end of each year

Year	P/S ratio	Change
2024	1.93	-0.24%
2023	1.93	-85.99%
2022	13.8	-51.25%
2021	28.3	406.59%
2020	5.58	-85.25%
2019	37.8	-0.84%
2018	38.2	-91.29%
2017	438	-85.13%
2016	> 1000	2339.11%
2015	121	68.86%
2014	71.6

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
Trevena TRVN	1.75	-33.90%	🇺🇸 USA
Flexion Therapeutics FLXN	N/A	N/A	🇺🇸 USA
Recro Pharma REPH	N/A	N/A	🇺🇸 USA
AcelRx Pharmaceuticals ACRX	22.4	744.30%	🇺🇸 USA
Pfizer PFE	2.51	-5.36%	🇺🇸 USA
Johnson & Johnson JNJ	3.98	50.14%	🇺🇸 USA
Acorda Therapeutics ACOR	0.0071	-99.73%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for Cara Therapeutics (CARA)

P/S ratio as of December 2024 (TTM): 2.65